CompletedPhase 2

TTHX1114(NM141) in Combination With DWEK/DSO

United States49 participantsStarted 2021-02-01

Plain-language summary

Open label, single-treatment, with a concurrent non-treatment control

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Key Inclusion Criteria: * Fuchs Endothelial Cell Dystrophy (FECD) diagnosed more than 6 months * Scheduled for DWEK/DSO with a planned central descemetorhexis of approx 4 to 5 mm * Subjects in Group 2 must have a stable Fellow Eye with adequate function Key Exclusion Criteria: * Secondary corneal/ocular pathology in the Study Eye * Prior refractive surgery in the Study Eye * Prior exposure to TTHX1114

What they're measuring

Best Corrected Visual Acuity

Timeframe: Day 28

Trial details

NCT IDNCT04676737

SponsorTrefoil Therapeutics, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-11-16

View on ClinicalTrials.gov More Fuchs' Endothelial Dystrophy trials